PATHOLOGY OF ADENOCARCINOMA OF THE PROSTATE--BIOLOGIC BEHAVIOR

我们的目标是开发和测试更好的方法， 定量评估前列腺癌的病理学， 加强检测和预后预测。 利用各种 图像分析系统结合常规组织学检查 参数，我们将分析1000个完全嵌入的自由基， 前列腺切除术标本。 我们的具体目标是：1）前瞻性 染色质纹理分析联合评价，核 形态计量学和DNA倍体作为疾病复发的预测因子 在420名男性中进行根治性乳房切除术后， T2 b期和T2 c期前列腺癌; 2）既往研究 未经测试的前列腺癌生物标志物可预测进展 在根治性直肠切除术后 这些包括：1）细胞死亡和 增殖标志物; 2）神经内分泌标志物; 3）血管生成 标记物; 4）脂肪酸合成酶（OA 519）; 5）BCL-2; 6）E-钙粘蛋白; 和7）8号染色体的荧光原位杂交（FISH）， 8 p和8 q; 3）染色质纹理的使用的研究， 核形态测量和其他各种生物标志物， 活检材料的预后信息; 4）前瞻性 验证发表在JAMA上的研究，以预测“微不足道” vs.基于穿刺活检结果和血清的“显著”疾病 前列腺特异性抗原（PSA）在前列腺癌患者中的应用; 5） 遗传性前列腺癌的病理学评价 利用DNA倍性、染色质结构、血清和组织 生物标志物和核形态测定; 6）临床和病理 研究评估新描述的单克隆抗体， 7）开发计算机辅助的PSA， 基于客观再现的建筑评分系统 肿瘤定量特征 上述研究旨在 区分相对惰性的前列腺癌， 可能是保守的管理，从那些更积极的 需要治疗的肿瘤 这个问题越来越重要， 随着早期的筛查技术的增强检测， 生物学恶性程度不确定的前列腺癌。的预测 肿瘤进展可能性较高的患者也将 需要用于辅助治疗的施用。

Our objective is to develop and test better methods of quantitatively evaluating the pathology of prostate cancer so as to enhance detection and prediction of prognosis. Utilizing various image analysis systems in conjunction with routine histologic parameters, we will analyze 1000 totally embedded radical prostatectomy specimens. Our specific aims are: 1) Prospective evaluation of combination of chromatin texture analysis, nuclear morphometry, and DNA ploidy as predictors of disease recurrence following radical prostatectomy in a group of 420 men with stage T2b and stage T2c prostate cancer; 2) Investigation of previously untested biomarkers for prostate cancers to predict progression following radical prostatectomy. These include: 1) cell death and proliferation markers; 2) neuroendocrine markers; 3) angiogenesis markers; 4) fatty acid synthase (OA519); 5) BCL-2; 6) E-cadherin; and 7) fluorescent in situ hybridization (FISH) for chromosomes 8, 8p, and 8q; 3) Investigation of the use of chromatin texture, nuclear morphometry and other various biomarkers to provide prognostic information on biopsy material; 4) Prospective validation of study published in JAMA to predict "insignificant" vs. "significant" disease based on needle biopsy findings and serum PSA measurements in men with non-palpable prostrate cancer; 5) Pathological evaluation of cases of hereditary prostate cancer utilizing DNA ploidy, chromatin texture, serum and tissue biomarkers, and nuclear morphometry; 6) Clinical and pathological studies evaluating the newly described monoclonal antibodies to bound and free forms of PSA, 7) Development of a computer assisted architectural grading system based on objective reproducible quantitative tumor characteristics. The above studies will aim to distinguish relatively indolent prostate cancers which could possibly be managed conservatively from those more aggressive tumors requiring therapy. This issue is increasingly important, with the enhanced detection by screening techniques of earlier prostate cancers of uncertain biologic malignancy. A prediction of patients with a higher probability for tumor progression will also be required for administering of adjuvant therapy.